Exelixis' Cabometyx scores backing from Ipsen in thyroid cancer, with full data release set for ASCO

Exelixis' flagship oncology drug Cabometyx has attracted a pharma partner to take it into a new type of cancer thanks to promising results in a pivotal trial.